53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
Hyfe pilot study tests a digital therapeutic combining passive cough monitoring with behavioral suppression techniques delivered through the CoughPro app.
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
Independent ERS 2025 NeuroCOUGH trial uses the Hyfe Cough Tracker to test feasibility of studying azithromycin's effect on cough and oesophageal motility.
Independent ERS 2025 trial uses the Hyfe Cough Tracker to show azithromycin reduces objective cough frequency by week one in chronic respiratory disease.
How long should you monitor a patient's cough to get a reliable picture of their burden? This ERS 2025 abstract from Hyfe's R&D team analyzed 60 days of continuous cough data from more than 30 individuals with chronic cough to answer that question quantitatively. Daily cough counts failed to conform to conventional statistical distributions, while hourly counts fit a zero-inflated negative binomial model, enabling simulations of the minimum monitoring duration needed for frequency estimates to fall within 20% of true values. Seven days proved sufficient for 83% of participants and for the full range of moderate cough variability seen in chronic cough populations; only the highest-variability cases required an eighth day to stabilize. The findings argue that the 24-hour monitoring window long used in cough research and drug development underestimates real-world variability, and offer a defensible, evidence-based standard for the field: monitor for a week.
